Biotech Breakthroughs Send Roivant and Pharvaris Stocks to New Peaks

Today the market saw two biotech names—Roivant Sciences (ROIV) and Pharvaris (PHVS)—climb to fresh all‑time highs, and it’s not by accident. Both companies announced encouraging data from late‑stage trials, and the news instantly lit up trading floors.

Roivant’s experimental lung‑disease medicine, Mosliciguat, wrapped up a Phase 2 study involving 135 patients. The headline number? A 56.3% drop in pulmonary vascular resistance (PVR) versus placebo after 16 weeks – the deepest reduction ever logged in a randomized pulmonary‑hypertension trial, according to H.C. Wainwright. On top of that, trial participants walked about 35 meters farther in the six‑minute walk test, and their NT‑proBNP levels—an indicator of cardiac stress—fell by roughly 53%.

Those figures seemed to convince analysts. H.C. Wainwright lifted Roivant’s price target from $41 to $47 and kept its “Buy” rating, labeling the results as a boost to what the firm calls Roivant’s third growth pillar. The market reacted quickly: ROIV stock was up more than 20% at the time of writing and has rallied nearly 92% year‑to‑date. On Stocktwits, retail sentiment flipped from bearish to “extremely bullish,” with message volumes spiking.

Half a world away, Pharvaris was celebrating its own milestone. The company’s oral drug, Deucrictibant XR, cleared the primary endpoint of a pivotal Phase 3 trial aimed at preventing hereditary angioedema (HAE). Patients taking the once‑daily pill saw an 83% reduction in HAE attacks compared with placebo; among those with Type 1 or Type 2 HAE, the drop was even steeper at 87%. Secondary goals were also met, and the safety profile was reassuring.

Pharvaris plans to translate those results into regulatory filings starting in the first half of 2027, including an FDA submission for a preventive HAE indication in the United States. The market cheered: PHVS shares jumped nearly 8% during the session and are up more than 43% for the year. Retail chatter on Stocktwits turned “extremely bullish” from neutral, with an “extremely high” volume of messages.

In short, solid data from two very different therapeutic areas—lung disease and rare‑genetic swelling—has reignited investor optimism in the biotech space. Whether you’re a long‑term holder or a trader looking for the next catalyst, the takeaway is clear: robust trial outcomes still move markets, and these two stocks are leading the charge right now.